Loading
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Previous close
$1.91
−$0.06 · -3.05%
Pre-market
$1.914
+$0.004 · +0.21%
Sep 11, 7:12 AM ET
Regular session · ET · Market data may be delayed.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Day range
Current $1.91
52-week range
Current $1.91
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
46
Fair Value
Sentiment
59
Mixed
Risk
68
High Risk
Momentum
74
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Day range
Current $1.91
52-week range
Current $1.91
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 229.38K USD | — | — | — |
| Gross profit | — | −229.38K USD | — | — | — |
| Research and development | 13.96M USD | 9.27M USD | 23.1M USD | 33.3M USD | 17.26M USD |
| Selling, general, and administrative | 8.51M USD | 8.57M USD | — | 11.55M USD | — |
| Operating expenses | 22.65M USD | 17.84M USD | 32.18M USD | 45.08M USD | 27.25M USD |
| Interest income | 596.77K USD | 853.03K USD | 1.14M USD | 562.26K USD | 44.08K USD |
| Interest expense | 17.9K USD | 332.72K USD | 2.89M USD | 4.3M USD | 2.16M USD |
| Depreciation and amortization | 178.34K USD | 229.38K USD | 229.38K USD | 229.38K USD | 229.38K USD |
| Operating income | −22.65M USD | −18.07M USD | −32.18M USD | −45.08M USD | −27.25M USD |
| Net income | −22.07M USD | −17.54M USD | −32.12M USD | −50.26M USD | −26.08M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
